Press release from the extraordinary shareholders' meeting of
Biovitrum (publ)
(Thomson Reuters ONE) - The information in this press release is not for release, publicationor distribution, directly or indirectly, in or into the UnitedStates, Australia, Canada, Hong Kong, Japan, South Africa,Switzerland or Singapore.At the extraordinary shareholders' meeting held on December 4th,2009, resolutions on the approval of the board's resolutionregarding the acquisition of Swedish Orphan International Holding ABand of the board's resolution on a rights issue as well as on anauthorization for the board to resolve on an issue of common sharesand convertible participating certificates (konvertiblavinstandelsbevis) against payment in kind or by way of set-off, wereadopted. In order to enable the rights issue the meeting alsoresolved to amend the articles of association. Further, a new boardmember and a new deputy chairman of the board of directors wereelected.All resolutions by the meeting were caused by the agreement betweenBiovitrum and the shareholders of Swedish Orphan InternationalHolding AB ("Swedish Orphan") pursuant to which Biovitrum shallacquire 100 per cent of the shares and warrants in Swedish Orphan(the "Transaction").Read the whole press release at:http://www.biovitrum.com/templates/InformationPage.aspx?id=818For further information, please contact:Biovitrum AB (publ)Martin Nicklasson, CEO BiovitrumPhone: +46 8 697 20 00Göran Arvidson, CFO BiovitrumPhone: +46 70 633 30 42Erik Kinnman, VP Investor Relations BiovitrumPhone: +46 73 422 15 40erik.kinnman(at)biovitrum.comAbout BiovitrumBiovitrum is an international pharmaceutical company that marketsspecialist pharmaceuticals in several regions. Using its expertiseand experience Biovitrum takes scientific innovation to patients withsignificant unmet medical need. Research expertise and capabilitiesare focused on development and production of biotechnologytherapeutics within our prioritized areas of hemophilia,inflammation/autoimmune diseases, cancer supportive care andmalabsorption. Biovitrum has revenues of approximately SEK 1.2billion and approximately 400 employees (prior to the Transaction).Biovitrum's head office is located in Sweden and the share is listedon the NASDAQ OMX Stockholm. For more information please visitwww.biovitrum.com.IMPORTANT NOTICE:The information in this press release is not for release, publicationor distribution, directly or indirectly, in or into the UnitedStates, Australia, Canada, Hong Kong, Japan, South Africa,Switzerland or Singapore.The information in this press release shall not constitute an offerto sell or the solicitation of an offer to buy, nor shall there beany sale of the securities referred to herein in any jurisdiction inwhich such offer, solicitation or sale would require preparation offurther prospectuses or other offer documentation, or be unlawfulprior to registration, exemption from registration or qualificationunder the securities laws of any such jurisdiction.The information in this press release does not constitute or form apart of any offer or solicitation to purchase or subscribe forsecurities in the United States. The securities mentioned herein havenot been, and will not be, registered under the United StatesSecurities Act of 1933 (the "Securities Act"). The securitiesmentioned herein may not be offered or sold in the United Statesabsent registration or an exemption from the registrationrequirements of the Securities Act. There will be no public offer ofsecurities in the United States.The information in this press release may not be forwarded ordistributed to any other person and may not be reproduced in anymanner whatsoever. Any forwarding, distribution, reproduction, ordisclosure of this information in whole or in part is unauthorized.Failure to comply with this directive may result in a violation ofthe Securities Act or the applicable laws of other jurisdictions.The above information has been made public in accordance with theSecurities Market Act and/or the Financial Instruments Trading Act.The information was published at 5.15 p.m. (CET) on December 4th,2009.http://hugin.info/134557/R/1359344/331306.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 04.12.2009 - 17:21 Uhr
Sprache: Deutsch
News-ID 9304
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 487 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Press release from the extraordinary shareholders' meeting of
Biovitrum (publ)"
steht unter der journalistisch-redaktionellen Verantwortung von
Biovitrum (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
